Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.

ABSTRACT:

Background

Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell (CTC) counts of ≥5 cells/7.5ml are associated with poor CRPC outcome.

Objective

To determine the value of a ≥30% CTC decline as a treatment response indicator.

Design, setting, and participants

We identified patients with a baseline CTC count ≥5 cells/7.5ml and evaluable post-treatment CTC counts in two prospective trials.

Intervention

Patients were treated in the COU-AA-301 (abiraterone after chemotherapy) and IMMC-38 (chemotherapy) trials.

Outcome measures and statistical analysis

The association between a ≥30% CTC decline after treatment and survival was evaluated using univariable and multiva

SUBMITTER: Lorente D 

PROVIDER: S-EPMC5568108 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature